Endometrial carcinoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | surveillance |
| Linked regimen | None |
| ID | IND-ENDOMETRIAL-STAGE-I-POLE-OBSERVATION |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-ESGO-ENDOMETRIAL-2025 SRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025 |
Notes
STUB — surveillance / observation track for Stage I endometrial with POLE-EDM or POLD1-EDM hypermutator phenotype. Requires clinical co-lead signoff. Orphan vs algorithm: ALGO-ENDOMETRIAL-STAGE-I does not yet exist; orchestrator should wire when authored. Existing algorithms (ALGO-ENDOMETRIAL-ADVANCED-1L, ALGO-ENDOMETRIAL-2L) are Stage IV and 2L respectively and intentionally untouched in this chunk.
Used By
Actionability
BMA-POLE-GERMLINE-POLYMERASE-PROOFREADING- POLE germline pathogenic variants in the exonuclease (proofreading) domain cause polymera...
Biomarker
BIO-POLD1-HYPERMUTATOR- POLD1 hypermutator phenotype (proofreading-domain mutation)BIO-POLE-HYPERMUTATOR- POLE hypermutator phenotype (proofreading-domain mutation)
Red flag
RF-POLE-POLD1-ENDOMETRIAL-LOW-RISK- Stage I endometrial carcinoma with pathogenic POLE or POLD1 exonuclease-domain mutation (...